Therapy for Type 2 Diabetes: Fundamental
Concepts for Primary Care
Module 1: Insulin 101: Fundamental concepts
Module 2: Premixed insulins
Module 3: Stepwise insulin regimens: From simple to sophisticated
Module 4: Concepts in meal planning for patients receiving insulin
Introduction
Irl B. Hirsch, MD, Professor of Medicine and Diabetes Treatment and Teaching Chair, University of Washington School of Medicine, reviews the basic concepts of the use of insulin in type 2 diabetes and provides a detailed discussion on premixed insulin preparations and insulin regimens that complements and broadens Dr. Einhorn’s audio webcast presentation on the use of insulin to manage type 2 diabetes. Dr. Hirsch also reviews meal planning concepts in the overall management of the type 2 diabetes patient on insulin therapy.
Intended Audience
This continuing medical education program is intended for primary care physicians and other healthcare professionals who manage patients with type 2 diabetes.
Educational Objectives
After completing this activity, participants should be better able to:
- Describe the fundamental concepts of the use of insulin in the patient with type 2 diabetes
- Evaluate the use of premixed insulin preparations
- Describe the different stepwise insulin regimens
- Apply meal planning concepts to patients receiving insulin.
Information on CME credit
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The American Medical Association designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Instructions for CME credit
This online enduring material is presented as an audio webcast with attendant slide presentation. To receive credit, please view all of the presentations of this CME activity and evaluate the content presented. Complete both the pre- and post-test and activity evaluation.
The estimated time to complete this activity, including pre-test, review of the materials, and self-assessment and evaluation is 1.0 hour.
Principal Faculty
Irl B. Hirsch, MD, Author/Presenter
Professor of Medicine
Diabetes Treatment and Teaching Chair
University of Washington School of Medicine
Seattle, WA
Stanley H. Hsia, MD, FRCPC, FACE, Planning Committee, Content Reviewer
Program Director, Endocrinology, Metabolism & Molecular Medicine
Associate Professor of Medicine, Division of Endocrinology and Metabolism
Charles R. Drew University of Medicine and Science
UCLA School of Medicine
Los Angeles, CA
Daniel Einhorn, MD, FACP, FACE, Planning Committee, Content Reviewer
Medical Director, Scripps Whittier Institute for Diabetes
Clinical Professor of Medicine, UCSD
President, Diabetes and Endocrine Associates
La Jolla, CA
Martin S. Lipsky, MD, Planning Commtitee, Content Reviewer
Dean, University of Illinois College of Medicine at Rockford
Professor, Department of Family and Community Medicine
Rockford, IL
Col. Robert A. Vigersky, MD, Planning Committee, Content Reviewer
Director, Diabetes Institute
Walter Reed Health Care System
Clinical Associate Professor, Department of Medicine
Georgetown University School of Medicine
Washington, DC
R. Mark Evans, PhD, Planning Commtitee
Director, Healthcare Education Products and Standards
American Medical Association
Chicago, IL
Kristi Eidsvoog, PhD, Planning Committee
Content Manager
MedEd Architects, LLC
Chicago, IL
Patti Fitzgerald, Planning Committee
Manager, Product Development, Healthcare Education Products and Standards
American Medical Association
Chicago, IL
Disclosure Policy
In order to assure the highest quality of CME programming, and to comply with the ACCME Standards for Commercial Support, the AMA requires that all faculty and planning committee members disclose relevant financial relationships with any commercial or proprietary entity producing health care goods or services relevant to the content being presented. We therefore obtain a completed disclosure and attestation form to inform the participant of any pertinent relationships disclosed, provided here.
These materials have been peer-reviewed by the members of the CME Advisory Board and the AMA Editorial Board to ensure the continued scientific accuracy and medical relevance of information presented and its independence from commercial bias. The AMA has control over all final content.
Dr. Einhorn: Research Grants, Aventis, Allergan, Lilly, Medtronic, Pfizer, sanofi-aventis;
Consultant, Amylin, Lilly, MannKind, Medtronic, Takeda; Speaker's Bureau,
Amylin, Merck, sanofi-aventis, Takeda; Significant Shareholder, MannKind.
Dr. Hirsch: Consultant, Eli Lilly, Novo Nordisk, Johnson & Johnson, Roche
Dr. Hsia: Consultant, Merck
Dr. Lipsky: Nothing relevant to disclose
Dr. Vigersky: Research Grants, DexCom, NovoNordisk, Pfizer, Roche; Stockholder, Merck
Dr. Eidsvoog: Nothing relevant to disclose
Dr. Evans: Nothing relevant to disclose
Ms. Fitzgerald: Nothing relevant to disclose
Acknowledgement of Support
This CME publication was supported through an independent education grant from Takeda Pharmaceuticals and produced in accordance with the AMA Standards for Industry-Supported Multimedia Continuing Medical Education and Other Communications.
Term of approval
Original Release Date- June 2008
Date of the Most Recent Review- July 2009
Expiration Date- December 2010
